DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Non-Small-Cell Lung Cancer (The Dynamic NSCLC Market: How Will European Payer and Physician Attitudes Shape This Highly Lucrative Market?) | Physician & Payer Forum | EU5 | 2015
The late-stage development pipeline for non-small-cell lung cancer (NSCLC) is one of the busiest pipelines in oncology, with approximately 25 novel therapies in Phase III development. Several of…
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Physician & Payer Forum | US | 2015
How Will U.S. Payer and Prescriber Attitudes Shape This Competitive Market? The treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL…
Current and Emerging Small-Molecule Targeted Agents in Key Oncology Indications | Physician & Payer Forum | Brazil and Mexico | 2015
Securing Market Share and Payer Acceptance in Increasingly Crowded and Segmented Markets in Brazil and Mexico Small molecule therapies offer specific targeting of the aberrant cellular…
Current and Emerging Small-Molecule Targeted Agents for NSCLC | Physician & Payer Forum | US | 2015
A Survey of Oncologists and MCO Pharmacy and Medical Directors Targeted small-molecule agents have emerged as key treatment options for biomarker-defined non-small-cell lung cancer (NSCLC)…
Non-Small-Cell Lung Cancer (Previously Treated; EGFR-Mutation-Positive/ALK-Translocation-Positive) | DecisionBase | US/EU5/Asia Pacific | 2015
In This Increasingly Crowded Setting, What Key Attributes Will Differentiate Emerging Therapies According to Oncologists and Payers? Treatment decisions for non-small-cell lung cancer (NSCLC)…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Brazil for Breast Cancer, NSCLC, CRC, and Malignant Melanoma | Physician & Payer Forum | Brazil and Mexico | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Brazil is highly dependent on incorporation into…
Oncology (Securing Favorable Reimbursement Status in the EU5 Oncology Markets: Evolving Physician and Payer Perspectives on Biomarker-Driven Prescribing in Oncology) | Physician & Payer Forum | EU5 | 2014
As oncology increasingly moves toward personalized approaches to therapy, the use of predictive biomarkers will become more important. A plethora of biomarker-driven brands are already available…
Biomarker-Driven Prescribing in Oncology: Stakeholder Dynamics in Mexico and Argentina for Breast Cancer, NSCLC, CRC and Malignant Melanoma | Physician & Payer Forum | Mexico and Argentina | 2014
Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
